Alkermes licences experimental MS therapy to Biogen
Dublin, Ireland-based Alkermes has licensed ALKS 8700, a novel, oral, small drug molecule in Phase III development for relapsing forms of multiple sclerosis, to US biotech Biogen.
Read More
Tag: ALKS 8700
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
